COMP <GO>
FTH vs MNPR // EV/EBITDA & P/E VALUATION
Faeth Therapeutics Inc. (NASDAQ) VS. Monopar Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: FTH 2
— MNPR 2
■ METRIC PARITY
LAST: $18.75 (-2.34%) • MKT CAP: $484.5M
valuation
—
LAST: $71.91 (-2.02%) • MKT CAP: $482.7M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (FTH VS. MNPR)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | FTH | MNPR | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -17.40% | -17.60 | MNPR | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -4.22% | -2.53% | -1.69 | MNPR | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 3/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 34.8 | 33.4 | +1.35 | FTH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $484.5M | $482.7M | $1.8M | FTH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | FTH REV | MNPR REV | FTH GROSS % | MNPR GROSS % | FTH FCF | MNPR FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$20.5M | -$12.2M |
| FY 2024 | $0 | $0 | — | — | -$24.8M | -$6.4M |
| FY 2023 | $0 | $0 | — | — | -$32.0M | -$7.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
FTH // BETA —
MNPR // BETA —